Kathryn Kilroy, Author at Synspire Pharmaceuticals

Studies led by Synedgen and Keck Graduate Institute show Ion-Sugar Interaction in Airway Mucus Has Implications for CF.This researchaddresses ion interactions in different kinds of cell surfaces and water-containing gels. Understanding how each type of ion affects the structure, electrical potential, and fluid behavior of the airway-surface layers in the lung has direct implications for designing drug targets that influence pulmonary behavior. Read on Cystic Fibrosis News Today

Life Science Leader features Synspira in its Companies to Watch

Posted on January 4, 2019 by Kathryn Kilroy

SNSP113 is a glycopolymer licensed to Synspira from Synedgen as one of the first therapeutic molecules that uses this research to target airway health. SNSP113 is set to soon enter a Phase 1b clinical trial for treating cystic fibrosis (CF). SNSP113 targets biofilms and restores normal mucus in the lungs of patients with cystic fibrosis. Other compounds in the pipeline target non-CF bronchiectasis, pulmonary infection, and chronic obstructive pulmonary disease (COPD) Read on Life Science Leader

Cystic Fibrosis News Today: Synspira’s Candidate SNSP113 Wins FDA Orphan Designation to Treat Bacterial Infections in Cystic Fibrosis

Posted on October 15, 2018October 30, 2018 by Kathryn Kilroy

Read on Cystic Fibrosis News Today

Synspire Pharmaceuticals Announces Abstracts Evaluating New Treatment Options for Cystic Fibrosis Complications Accepted for Presentation at the 32nd Annual North American Cystic Fibrosis Conference

Posted on October 12, 2018May 10, 2023 by Kathryn Kilroy

Continue reading “Synspire Pharmaceuticals Announces Abstracts Evaluating New Treatment Options for Cystic Fibrosis Complications Accepted for Presentation at the 32nd Annual North American Cystic Fibrosis Conference”

BusinessWire: Synspira Receives U.S. FDA Orphan Designation

Posted on October 11, 2018October 30, 2018 by Kathryn Kilroy

Read on BusinessWire